ZSAN Zosano Pharma Corporation

1.20
-0.09  -6.98%
Previous Close 1.29
Open 1.21
Price To book 1.81
Market Cap 20.18M
Shares 16,815,000
Volume 263,165
Short Ratio 1.31
Av. Daily Volume 136,390

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced treatment of last patient - January 5, 2017. Pivotal trial data due 1Q 2017.
ZP-Triptan
Migraine
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
ZP-Glucagon
Severe hypoglycemia

Latest News

  1. Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
  2. Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
  3. Zosano Pharma Announces Sale of Non-Strategic Asset
  4. ZOSANO PHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  5. Zosano Pharma Announces Sale of Non-Strategic Asset
  6. ZOSANO PHARMA CORP Financials
  7. ZOSANO PHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
  8. Zosano Pharma Reports Third Quarter 2016 Financial Results
  9. Zosano Pharma Reports Third Quarter 2016 Financial Results
  10. Zosano Pharma Announces Completion of Enrollment in Pivotal Efficacy Trial for M207 for Acute Migraine
  11. Zosano Pharma Announces Completion of Enrollment in Pivotal Efficacy Trial for M207 for Acute Migraine
  12. ZOSANO PHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  13. ZOSANO PHARMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
  14. SHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Zosano Pharma Corporation and Encourages Investors with Losses to Contact the Firm
  15. Zosano Announces Inducement Grant for Georgia Erbez, Chief Business Officer
  16. ZOSANO PHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  17. Zosano Appoints Georgia Erbez as Chief Business Officer
  18. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Zosano Pharma Corporation - ZSAN
  19. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of Zosano Pharma Corporation (ZSAN)
  20. IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Zosano Pharma Corporation and Advises Investors With Losses in Excess of $10,000 Contact the Firm

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 17509854
  2. 8-K - Current report 162014050
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 162001973
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161984742
  5. 8-K - Current report 161984694
  6. 8-K - Current report 161971728
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 161939276
  8. 8-K - Current report 161937185
  9. DEF 14A - Other definitive proxy statements 161928223
  10. 424B3 - Prospectus [Rule 424(b)(3)] 161901320